Skip to main content

Aspirin in Reducing Events in the Elderly (ASPREE)

Active, not recruiting

The ASPREE study will examine whether the potential benefits of low-dose aspirin (particularly preventing heart disease, stroke, certain cancers, and dementia) outweigh the risks (particularly bleeding) in people over age 70. ASPREE will determine whether taking a daily low-dose aspirin will extend the length of a disability-free life in healthy participants aged 70 years and above.

Minimum Age Maximum Age Gender Healthy Volunteers
70 Years Both Accepts Healthy Volunteers
January 2010
January 2019
19000

++Men and women 70 years of age and over

++History of a diagnosed cardiovascular event++Serious intercurrent illness likely to cause death within the next 5 years, such as terminal cancer or obstructive airways disease++Current or recurrent condition with a high risk of major bleeding, for example, cerebral aneurysm++Anemia++Current participation in a clinical trial++Systolic blood pressure of ≥180 mmHg and/or diastolic blood pressure of ≥105 mmHg++History of dementia++Severe difficulty or inability to perform any one of the 6 Katz activities of daily living++Noncompliance to taking pill++Absolute contraindication or allergy to aspirin++Current continuous use of aspirin or other antiplatelet drug or anticoagulant for secondary prevention; people with previous use of aspirin for primary prevention may enter the trial, provided they agree to cease existing use of aspirin and understand that they may be subsequently randomly allocated to low-dose aspirin or placebo

Low-dose aspirin therapy has been shown to reduce the risk of vascular events, largely in middle-aged people. There is also some evidence of its potential to reduce the rate of intellectual decline and certain types cancers in older participants. However, these benefits may be offset by adverse effects, such as potential bleeding. The balance of risks and benefits of low-dose aspirin has not been established in older persons. Previous studies on the effects of aspirin in primary prevention have mainly focused on cardiovascular outcomes. In the elderly, these outcomes alone may not be the most appropriate measure of benefit associated with aspirin treatment. Prolonging a life free of functional disability in a healthy aging population would be the most desirable benefit of aspirin as a preventive medicine.

If you are interested in joining ASPREE, please contact a location near you from the list below. For more information about this trial, visit the ASPREE website.

Name City State Zip Status Primary Contact
The University of Alabama at Birmingham
Birmingham Alabama 35294

Palo Alto Medical Foundation Research Institute
Palo Alto California 94301

Howard University
Washington District of Columbia 20060

University of Florida Department of Aging and Geriatrics
Gainesville Florida 32611

Morehouse School of Medicine
Atlanta Georgia 30310

Emory/ Atlanta VAMC
Atlanta Georgia 30322

Georgia Health Sciences University
Augusta Georgia 30912

Rush Alzheimer's Disease Center
Chicago Illinois 60612

University of Iowa
Iowa City Iowa 52242

Kansas University Medical Center
Kansas City Kansas 66106

Pennington Biomedical Research Center
Baton Rouge Louisiana 70808

Mary Bird Perkins Our Lady of the Lake Cancer Center
Baton Rouge Louisiana 70809

LSU Health Sciences- New Orleans
New Orleans Louisiana 70112

Tulane Medical Center
New Orleans Louisiana 70112

LSU Health Sciences- Shreveport
Shreveport Louisiana 71130

University of Michigan
Ann Arbor Michigan 48109

Wayne State University
Detroit Michigan 48201

Henry Ford Health System
Detroit Michigan 48202

Detroit Clinical Research Center
Novi Michigan 48377

Health Partners Research Foundation
Minneapolis Minnesota 55425

Phalen Village Clinic
Saint Paul Minnesota 55106

Central Jersey Medical Center
Elizabeth New Jersey 07202

Winthrop University Hospital
Mineola New York 11501

Wake Forest University Baptist Medical Center
Greensboro North Carolina 27408

The Brody School of Medicine at ECU
Greenville North Carolina 27834

Albert Einstein Medical Center
Philadelphia Pennsylvania 19141

University of Pittsburgh Health Sciences Research Center
Pittsburgh Pennsylvania 15260

Memorial Hospital of Rhode Island
Pawtucket Rhode Island 02860

University of Tennessee Health Science Center
Memphis Tennessee 38105

University of Texas Southwestern Medical Center at Dallas
Dallas Texas 75390

University of TX Medical Branch
Galveston Texas 77555

Regional Academic Health Center
Harlingen Texas 78550

UT Health Science Center at San Antonio
San Antonio Texas 78229

Minneapolis Medical Research Foundation

  • National Health and Medical Research Council, Australia
  • Bayer
  • Monash University
  • Berman Center for Outcomes and Clinical Research

Name Role Affiliation
Richard Grimm, MD, PhD Principal Investigator Berman Center for Outcomes and Clinical Research
John McNeil, MD Principal Investigator Monash University

Name Phone Email
Nathan J. Tessum 612-341-7907 ntessum@bermancenter.org
Brenda Kirpach 612-341-7922 bkirpach@bermancenter.org

NCT01038583

Aspirin in Reducing Events in the Elderly